More than a million French people are affected by age-related macular degeneration (AMD) and, after 75 years, one in four people is confronted with this visual disorder which causes a progressive loss of the possibility of reading, use screens or recognize faces, and that can lead to blindness.
The only treatments available target vascular complications, such as the monoclonal antibody marketed in 2006 under the name Lucentis (ranibizumab).
But it is only indicated in so-called “wet” AMD, ie less than 20% of cases.
Food supplements have been shown to be effective in slowing the progression of the disease, but experts remain divided on their real interest, especially in patients with a varied diet.
All, however, agree on the benefits of stopping smoking, recognized as an aggravating factor.
Read also
Restoring vision, a dream made possible by technological innovations
Fortunately,
"recent advances in eye imaging open up new perspectives
,"
This article is for subscribers only.
You have 65% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in